Analytical Data
-
Gene name
HLA-E*01:03&B2M&CMV UL40(VMAPRTVIL) Monomer
- Application
-
Alternative Names
HLA-E*0103 & B2M & CMV UL40 (VMAPRTVIL)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P13747 (G22-I305)&P61769
-
Expression Region
P13747 (G22-I305)&P61769 (I21-M119)&VMAPRTVIL
-
Molecular Weight
40-43 kDa and 12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-E*01:03/B2M/CMV UL40 (VMAPRTVIL) monomer is a recombinant protein that is critical for understanding immune responses mediated by the major histocompatibility complex (MHC) class I. HLA-E is a non-classical MHC molecule that plays a vital role in immune regulation by presenting peptides from the UL40 protein of cytomegalovirus (CMV) to natural killer (NK) cells. The peptide VMAPRTVIL, derived from CMV, effectively binds to HLA-E, enabling the recognition and modulation of NK cell activity. Research on this specific recombinant protein is essential for clarifying how HLA-E interacts with both the innate and adaptive immune systems, particularly in the context of viral infections and potential therapeutic applications. Understanding this interaction can provide insights into immune evasion strategies employed by pathogens and contribute to the development of new immunotherapeutic approaches, especially in the context of diseases such as CMV infections, cancer, and transplantation. Thus, the study of the HLA-E*01:03/B2M/CMV UL40 monomer combines molecular biology, immunology, and virology, making it an important focus for advancing our knowledge of immune responses and for potential clinical applications.
